.png){kind=icon}
.png){kind=icon}
Return
Reporting Quality of Randomized Controlled Trials Published in <i>Integrative Cancer Therapies</i> : Evaluation Against CONSORT 2010 and Perspectives for CONSORT 2025
.png){kind=icon}
PRE
AI
G
S
F
X
H
DOI：10.1177/15347354261464521.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
<jats:p>
Consolidated Standards of Reporting Trials (CONSORT) 2025 Statement was issued in April 2025, however, no dedicated CONSORT extension currently exists for integrative oncology. It is therefore essential to provide practical recommendations, grounded in the CONSORT 2025 Statement and in an analysis of randomized controlled trials (RCT) reporting quality against CONSORT 2010, to guide future RCTs. This study presents a literature-based analysis of RCTs published in
<jats:italic toggle="yes">Integrative Cancer Therapies</jats:italic>
between 2010 and 2025, describing study characteristics and overall weighted adherence to CONSORT 2010 of 72 included RCTs. The annual number of publications exhibited an overall upward trend over the past 15 years; overall weighted adherence to CONSORT 2010 across the 72 studies was 67.9%, and the mean per-manuscript adherence was 67.2%. Drawing on this analysis and the CONSORT 2025 update, several specific measures are proposed to improve the reporting quality of RCTs in integrative oncology.
</jats:p>
Journal
IF:
2.8
Papers:
171
Citations:
3.5K
Organization
Cited Papers